Scan to downloadEisai Co., Ltd. (4523) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-11-10 | — | CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2026 | |
| 2026-11-10 | Earnings Release | Financial Results for the Six-Month Period Ended September 30,2026 Reference Data | |
| 2026-10-28 | — | Revenue of LEQEMBI (Preliminary Basis) | |
| 2026-10-02 | — | Notification Regarding Receipt of Dividend from a Consolidated Subsidiary | |
| 2026-09-16 | — | LEQEMBI Pen (Subcutaneous Formulation of LEQEMBI) Approved in Japan | |
| 2026-09-03 | — | LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China | |
| 2026-08-03 | — | CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026 | |
| 2026-08-03 | Earnings Release | FY2026(Ending March 31,2027) First Quarter Financial Results Reference Data | |
| 2026-07-29 | — | Revenue of LEQEMBI (Preliminary Basis) | |
| 2026-07-14 | — | FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.